Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec Parent Inc., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-20.85M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 200.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1030.07% |
| Return on Assets (Trailing 12 Months) | -299.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-15.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 113.24M |
| Free Float | 86.52M |
| Market Capitalization | $250.27M |
| Average Volume (Last 20 Days) | 0.10M |
| Beta (Past 60 Months) | 1.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.06% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |